Login to Your Account



2nd Zealand, Boehringer Ingelheim diabetes deal worth up to $396M

By Cormac Sheridan
Staff Writer

Monday, July 28, 2014
Zealand Pharma A/S could earn up to €295 million (US$396 million) in milestone payments arising from a second drug development deal in diabetes with Boehringer Ingelheim GmbH. It will bank €5.6 million during 2014.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription